{"id":103107,"date":"2025-03-28T09:11:33","date_gmt":"2025-03-28T08:11:33","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\/"},"modified":"2025-10-13T15:11:36","modified_gmt":"2025-10-13T13:11:36","slug":"gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/es\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\/","title":{"rendered":"Gain Therapeutics anuncia la administraci\u00f3n de su f\u00e1rmaco GT-02287 al primer paciente del ensayo cl\u00ednico en fase 1b para la enfermedad de Parkinson"},"content":{"rendered":"<p><strong>La compa\u00f1\u00eda biotecnol\u00f3gica en fase cl\u00ednica, <a href=\"https:\/\/www.pcb.ub.edu\/es\/empresa\/gain-therapeutics\/\" target=\"_blank\" rel=\"noopener\">Gain Therapeutics<\/a>, ha anunciado la administraci\u00f3n de la primera dosis a un participante con enfermedad de Parkinson en su ensayo cl\u00ednico de fase 1b de GT-02287, su principal mol\u00e9cula peque\u00f1a alost\u00e9rica en desarrollo para el tratamiento de la enfermedad. La compa\u00f1\u00eda suiza, l\u00edder en el descubrimiento y desarrollo de la pr\u00f3xima generaci\u00f3n de terapias alost\u00e9ricas de mol\u00e9culas peque\u00f1as, tiene su departamento de R+D en el Parque Cient\u00edfico de Barcelona.<\/strong><\/p>\n<p>Se trata del principal f\u00e1rmaco candidato de Gain Therapeutics, en pleno desarrollo cl\u00ednico para el tratamiento del Parkinson, con o sin mutaci\u00f3n en el gen GBA1, el principal factor de riesgo gen\u00e9tico para desarrollar la enfermedad. GT-02287 es una mol\u00e9cula peque\u00f1a de administraci\u00f3n oral y con capacidad para penetrar en el cerebro. Act\u00faa como un modulador alost\u00e9rico de la enzima glucocerebrosidasa (GCase), restaurando su funci\u00f3n cuando esta se ve alterada por mutaciones en el gen GBA1 o por factores de estr\u00e9s asociados a la edad.<\/p>\n<p>En estudios precl\u00ednicos realizados, GT-02287 ayud\u00f3 a restaurar la enzima GCase, redujo la inflamaci\u00f3n y la acumulaci\u00f3n de prote\u00ednas da\u00f1inas en el cerebro, y consigui\u00f3 mejorar el movimiento y la memoria. Adem\u00e1s, tambi\u00e9n disminuy\u00f3 los niveles de NfL en plasma, un biomarcador de neurodegeneraci\u00f3n. Estos resultados sugieren que GT-02287 podr\u00eda ayudar a frenar o detener la progresi\u00f3n del Parkinson, tanto en casos con una mutaci\u00f3n gen\u00e9tica como en formas sin causa conocida.<\/p>\n<p>\u201cEl inicio de la administraci\u00f3n en nuestro ensayo cl\u00ednico de fase 1b representa un paso importante en el desarrollo cl\u00ednico de GT-02287 y en la misi\u00f3n de Gain Therapeutics de ofrecer una terapia que modifique el curso de la enfermedad para las personas con Parkinson. Esperamos continuar con la inscripci\u00f3n de participantes y anticipamos un an\u00e1lisis intermedio hacia finales del segundo trimestre de 2025\u201d afirma <strong>Gene Mack<\/strong>, presidente y CEO de la compa\u00f1\u00eda.<\/p>\n<p>El ensayo cl\u00ednico de fase 1b, abierto y realizado en varios centros, tiene como objetivo evaluar la seguridad y tolerabilidad de GT-02287 en personas con Parkinson asociado a GBA1 y Parkinson idiop\u00e1tico, analizando tambi\u00e9n la farmacocin\u00e9tica, la modulaci\u00f3n de GCase y los biomarcadores en plasma y l\u00edquido cefalorraqu\u00eddeo. El estudio incluir\u00e1 hasta 20 participantes que recibir\u00e1n el tratamiento durante tres meses, con datos intermedios esperados a finales del segundo trimestre de 2025.<\/p>\n<p>El principal programa de la compa\u00f1\u00eda ha recibido apoyo financiero desde las primeras etapas de su desarrollo por parte de The Michael J. Fox Foundation for Parkinson\u2019s Research (MJFF) y The Silverstein Foundation for Parkinson\u2019s with GBA, as\u00ed como del programa conjunto Eurostars-2, con cofinanciaci\u00f3n de la Uni\u00f3n Europea a trav\u00e9s del programa Horizonte 2020 y de Innosuisse \u2013 Agencia Suiza de Innovaci\u00f3n.<\/p>\n<p><strong>\u00bb Enlace a la noticia:<\/strong> <a href=\"https:\/\/gaintherapeutics.com\/newsroom\/press-releases\/press-releases-2025\/gain-therapeutics-doses-first-participant-in-phase-1b-clinical-trial-of-gt-02287-in-parkinsons-disease\/\" target=\"_blank\" rel=\"noopener\">web de GAIN Therapeutics [+]<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La compa\u00f1\u00eda biotecnol\u00f3gica en fase cl\u00ednica, Gain Therapeutics, ha anunciado la administraci\u00f3n de la primera dosis a un participante con enfermedad de Parkinson en su ensayo cl\u00ednico de fase 1b&#8230;<\/p>\n","protected":false},"author":1,"featured_media":103100,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[356],"tags":[290],"class_list":["post-103107","post","type-post","status-publish","format-standard","has-post-thumbnail","category-empresas","tag-gain-therapeutics-es"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gain Therapeutics anuncia la administraci\u00f3n de su f\u00e1rmaco GT-02287 al primer paciente del ensayo cl\u00ednico en fase 1b para la enfermedad de Parkinson - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"description\" content=\"La compa\u00f1\u00eda biotecnol\u00f3gica en fase cl\u00ednica, Gain Therapeutics, ha anunciado la administraci\u00f3n de la primera dosis a un participante con enfermedad de Parkinson en su ensayo cl\u00ednico de fase 1b de GT-02287, su principal mol\u00e9cula peque\u00f1a\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/es\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gain Therapeutics anuncia la administraci\u00f3n de su f\u00e1rmaco GT-02287 al primer paciente del ensayo cl\u00ednico en fase 1b para la enfermedad de Parkinson - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"La compa\u00f1\u00eda biotecnol\u00f3gica en fase cl\u00ednica, Gain Therapeutics, ha anunciado la administraci\u00f3n de la primera dosis a un participante con enfermedad de Parkinson en su ensayo cl\u00ednico de fase 1b de GT-02287, su principal mol\u00e9cula peque\u00f1a\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/es\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-28T08:11:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-13T13:11:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/03\/Adobe-Express-file-13.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"adminpcb\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminpcb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\\\/\"},\"author\":{\"name\":\"adminpcb\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"headline\":\"Gain Therapeutics anuncia la administraci\u00f3n de su f\u00e1rmaco GT-02287 al primer paciente del ensayo cl\u00ednico en fase 1b para la enfermedad de Parkinson\",\"datePublished\":\"2025-03-28T08:11:33+00:00\",\"dateModified\":\"2025-10-13T13:11:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\\\/\"},\"wordCount\":531,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/Adobe-Express-file-13.jpg\",\"keywords\":[\"GAIN Therapeutics\"],\"articleSection\":[\"EMPRESAS\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\\\/\",\"name\":\"Gain Therapeutics anuncia la administraci\u00f3n de su f\u00e1rmaco GT-02287 al primer paciente del ensayo cl\u00ednico en fase 1b para la enfermedad de Parkinson - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/Adobe-Express-file-13.jpg\",\"datePublished\":\"2025-03-28T08:11:33+00:00\",\"dateModified\":\"2025-10-13T13:11:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"description\":\"La compa\u00f1\u00eda biotecnol\u00f3gica en fase cl\u00ednica, Gain Therapeutics, ha anunciado la administraci\u00f3n de la primera dosis a un participante con enfermedad de Parkinson en su ensayo cl\u00ednico de fase 1b de GT-02287, su principal mol\u00e9cula peque\u00f1a\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/Adobe-Express-file-13.jpg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/Adobe-Express-file-13.jpg\",\"width\":900,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gain Therapeutics anuncia la administraci\u00f3n de su f\u00e1rmaco GT-02287 al primer paciente del ensayo cl\u00ednico en fase 1b para la enfermedad de Parkinson\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\",\"name\":\"adminpcb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"caption\":\"adminpcb\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/author\\\/adminpcb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gain Therapeutics anuncia la administraci\u00f3n de su f\u00e1rmaco GT-02287 al primer paciente del ensayo cl\u00ednico en fase 1b para la enfermedad de Parkinson - Parc Cient\u00edfic de Barcelona","description":"La compa\u00f1\u00eda biotecnol\u00f3gica en fase cl\u00ednica, Gain Therapeutics, ha anunciado la administraci\u00f3n de la primera dosis a un participante con enfermedad de Parkinson en su ensayo cl\u00ednico de fase 1b de GT-02287, su principal mol\u00e9cula peque\u00f1a","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/es\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\/","og_locale":"es_ES","og_type":"article","og_title":"Gain Therapeutics anuncia la administraci\u00f3n de su f\u00e1rmaco GT-02287 al primer paciente del ensayo cl\u00ednico en fase 1b para la enfermedad de Parkinson - Parc Cient\u00edfic de Barcelona","og_description":"La compa\u00f1\u00eda biotecnol\u00f3gica en fase cl\u00ednica, Gain Therapeutics, ha anunciado la administraci\u00f3n de la primera dosis a un participante con enfermedad de Parkinson en su ensayo cl\u00ednico de fase 1b de GT-02287, su principal mol\u00e9cula peque\u00f1a","og_url":"https:\/\/www.pcb.ub.edu\/es\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2025-03-28T08:11:33+00:00","article_modified_time":"2025-10-13T13:11:36+00:00","og_image":[{"width":900,"height":330,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/03\/Adobe-Express-file-13.jpg","type":"image\/jpeg"}],"author":"adminpcb","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"adminpcb","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/es\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\/"},"author":{"name":"adminpcb","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"headline":"Gain Therapeutics anuncia la administraci\u00f3n de su f\u00e1rmaco GT-02287 al primer paciente del ensayo cl\u00ednico en fase 1b para la enfermedad de Parkinson","datePublished":"2025-03-28T08:11:33+00:00","dateModified":"2025-10-13T13:11:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\/"},"wordCount":531,"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/03\/Adobe-Express-file-13.jpg","keywords":["GAIN Therapeutics"],"articleSection":["EMPRESAS"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/es\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\/","url":"https:\/\/www.pcb.ub.edu\/es\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\/","name":"Gain Therapeutics anuncia la administraci\u00f3n de su f\u00e1rmaco GT-02287 al primer paciente del ensayo cl\u00ednico en fase 1b para la enfermedad de Parkinson - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/03\/Adobe-Express-file-13.jpg","datePublished":"2025-03-28T08:11:33+00:00","dateModified":"2025-10-13T13:11:36+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"description":"La compa\u00f1\u00eda biotecnol\u00f3gica en fase cl\u00ednica, Gain Therapeutics, ha anunciado la administraci\u00f3n de la primera dosis a un participante con enfermedad de Parkinson en su ensayo cl\u00ednico de fase 1b de GT-02287, su principal mol\u00e9cula peque\u00f1a","breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/es\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/es\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.pcb.ub.edu\/es\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/03\/Adobe-Express-file-13.jpg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/03\/Adobe-Express-file-13.jpg","width":900,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/es\/gain-therapeutics-anuncia-la-administracion-de-su-farmaco-gt-02287-al-primer-paciente-del-ensayo-clinico-en-fase-1b-para-la-enfermedad-de-parkinson\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/es\/"},{"@type":"ListItem","position":2,"name":"Gain Therapeutics anuncia la administraci\u00f3n de su f\u00e1rmaco GT-02287 al primer paciente del ensayo cl\u00ednico en fase 1b para la enfermedad de Parkinson"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021","name":"adminpcb","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","caption":"adminpcb"},"url":"https:\/\/www.pcb.ub.edu\/es\/author\/adminpcb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/103107","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/comments?post=103107"}],"version-history":[{"count":1,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/103107\/revisions"}],"predecessor-version":[{"id":103111,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/103107\/revisions\/103111"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media\/103100"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media?parent=103107"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/categories?post=103107"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/tags?post=103107"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}